Clinical Trials Directory

Trials / Completed

CompletedNCT02020707

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.

Detailed description

PRIMARY OBJECTIVES: I. To determine the maximally tolerated dose (MTD-malignant melanoma \[MM\]) of Abraxane (nab-paclitaxel)/bevacizumab-complex (AB-complex) among patients with metastatic malignant melanoma. II. To determine the maximally tolerated dose (MTD-gynecologic \[GYN\]) of AB-complex among patients with gynecologic cancers. III. To further assess the safety profile and anti-tumor activity of the recommended phase II dose of AB-complex for patients with previously-treated endometrial cancer IV. To further assess the safety profile and anti-tumor activity of the recommended phase II dose of AB-complex for patients with previously treated ovarian cancer SECONDARY OBJECTIVES: I. To gather preliminary data on tumor response rate and progression free survival time of AB-complex among patients with metastatic malignant melanoma. II. To gather preliminary data on tumor response rate and progression free survival time of AB-complex among patients with gynecologic cancers. CORRELATIVE OBJECTIVES (DOSE-ESCALATION COHORTS ONLY): I. Pharmacokinetics of paclitaxel administered in the context of AB-complex. II. Tumor concentrations of paclitaxel 24 hour (h) following AB-complex infusion and correlation with plasma levels. OUTLINE: This is a dose-escalation study. Patients receive nab-paclitaxel/bevacizumab-complex intravenously (IV) over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted. After completion of study treatment, patients are followed up every 6 months for 12 months.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBevacizumabGiven IV
OTHERLaboratory Biomarker AnalysisCorrelative studies
DRUGNab-paclitaxelGiven IV
OTHERPharmacological StudyCorrelative studies

Timeline

Start date
2014-02-24
Primary completion
2024-07-18
Completion
2024-07-18
First posted
2013-12-25
Last updated
2024-07-26

Locations

4 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02020707. Inclusion in this directory is not an endorsement.